Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 11/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652327 | 0.82 | PTGER4 (0.49) | PTGER4PIN1NPC1 | |
| SCHEMBL2661770 | 0.80 | PPARG (0.52) | HDAC1HDAC6SIRT2 | |
| SCHEMBL2651903 | 0.80 | HDAC1 (0.41) | HDAC1HDAC6SIRT2 | |
| SCHEMBL2653452 | 0.79 | RIPK2 (0.45) | PTGER4HDAC6SIRT2PIN1NPC1 | |
| SCHEMBL9251208 | 0.76 | ITGB3 (0.53) | PTGER4SIRT2EPHX2 | |
| SCHEMBL2651445 | 0.76 | MRGPRX1 (0.49) | PTGER4PIN1NPC1 | |
| SCHEMBL2661876 | 0.75 | PTGER4 (0.51) | PTGER4PIN1RIPK2 | |
| SCHEMBL9255722 | 0.75 | SIRT2 (0.51) | PTGER4SIRT2EPHX2 | |
| SCHEMBL9246297 | 0.75 | PTGER4 (0.58) | PTGER4RIPK2 | |
| Bromide SCHEMBL9248603 | 0.74 | SIRT2 (0.51) | PTGER4SIRT2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | PTGER4 412/4885HDAC1 3760/4885HDAC6 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.